Aldeyra Therapeutics Inc
Închisă
1.53 6.99
Rezumat
Modificarea prețului
24h
Minim
1.43
Maxim
1.56
Venit | -8.9B -8.9B |
|---|---|
EPS | -0.16 |
Angajați | 7 |
EBITDA | -2.5M -5.5M |
Următoarele câștiguri | 3 nov. 2026 |
|---|
Capitalizare de piață | -1.2M 91M |
|---|---|
Deschiderea anterioară | -5.46 |
Închiderea anterioară | 1.53 |
Aldeyra Therapeutics Inc Grafic
Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.
Știri relevante
Comparație
Modificare preț
Aldeyra Therapeutics Inc Așteptări
Date financiare
Cheltuieli de vânzare și administrare
Cheltuieli de exploatare
Profit pre-impozitare
Vânzări
Costul vânzărilor
Profit brut din vânzări
Cheltuieli cu dobânzile pe datorie
EBITDA
Profit operațional
$
Despre Aldeyra Therapeutics Inc
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.